Objectives: To compare antibiotic optimization and outcomes of patients before implementation of the Verigene Gram-Positive Blood Culture (Verigene BC-GP) nucleic acid microarray assay to after implementation with antimicrobial stewardship (AS) interventions and after discontinuation of AS interventions.
Introduction
Administration of early, optimal antibiotic therapy is critical to improving patient outcomes. In recent years, a number of molecular rapid diagnostic assays have been developed to reduce the time to organism and resistance marker detection. Evaluations of these assays demonstrate that they are rapid, accurate, and associated with reduced time to optimal antibiotic therapy and in some cases mortality. [1] [2] [3] [4] [5] However, in published reports these benefits are only realized when these tests are combined with antimicrobial stewardship (AS) interventions. 5 The Verigene Gram-Positive Blood Culture (Verigene BC-GP) nucleic acid test (Nanosphere, Inc., Northbrook, IL, USA) is a multiplex molecular test that identifies Gram-positive organisms to the genus level (Staphylococcus spp., Streptococcus spp. and Listeria spp.) and to the species level (Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, the Streptococcus anginosus group, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis and Enterococcus faecium). Additionally, the assay identifies three resistance markers: mecA, vanA and vanB. The Verigene BC-GP assay has been associated with high levels of agreement for organism identification and resistance marker detection compared with established laboratory methods. [7] [8] [9] AS interventions in combination with the Verigene BC-GP assay have been shown to decrease the time to optimal therapy, duration of antibiotic therapy for contaminated blood cultures and length of hospital stay. [10] [11] [12] [13] [14] However, data are lacking regarding whether clinicians learn to interpret and act upon the results of this assay and whether clinical benefits remain when associated AS interventions are discontinued. The objective of this study was to compare antibiotic optimization and outcomes of patients with Grampositive cocci (GPC) bacteraemia prior to introduction of the assay, during introduction of the assay coupled with AS interventions, and after AS interventions have been discontinued.
Methods

Setting and patients
This was a retrospective study conducted at the Johns Hopkins Hospital (JHH), a 1194 bed tertiary care centre in Baltimore, MD, USA. Adult patients at least 18 years of age hospitalized between 6 August 2012 and 5 May 2014 with GPC bacteraemia were included. Patients were excluded if they met any of the following criteria: positive blood cultures with known antimicrobial susceptibility testing (AST) results prior to hospital admission, failure of Verigene BC-GP to identify at least one organism, or death before culture results were available. Patients were included only once per study period. Patients with polymicrobial Gram-positive bacteraemia were included, with the most clinically relevant organism selected as the primary pathogen.
Ethics
The study was approved by the Institutional Review Board of the Johns Hopkins University School of Medicine, with a waiver of informed consent.
Laboratory methods and protocol
The Johns Hopkins Hospital Medical Microbiology Laboratory implemented the Verigene BC-GP on 3 March 2013, after extensive validation. Prior to this date, blood cultures growing GPC were evaluated for organism identification and AST using the BD Phoenix Automated Microbiology System (BD Diagnostics, Sparks, MD, USA). In addition, peptide nucleic acid fluorescence in situ hybridization (PNA FISH) was performed on all positive blood cultures for GPC in chains. Implementation of PNA FISH at our institution was not combined with AS interventions. 15 The Verigene BC-GP assay was performed only on the first blood culture growing GPC, 24 h per day and 7 days per week, according to the manufacturer's instructions. 6 The assay was not performed on blood cultures if more than one morphology of GPC was present on Gram staining. Assay results were reported within 4 h of the first positive Gram stain. Providers were notified by telephone calls from the microbiology laboratory as soon as blood cultures demonstrated bacterial growth during all study periods. Preliminary Gram stain results were reported in the electronic medical record and results were updated in real time as they became available. No additional calls were made when the Verigene BC-GP results became available. Verigene BC-GP and AST results were reported in the electronic medical record. S. aureus isolates positive for mecA were reported as MRSA and S. aureus isolates negative for mecA were reported as MSSA. E. faecium and E. faecalis isolates that were positive for vanA/vanB were reported as VRE. S. epidermidis was reported as CoNS and mecA results were not reported for these isolates. Single positive blood cultures for CoNS were reported as possible contaminants. The microbiology laboratory protocol related to GPC bacteraemia during each study period is summarized in Figure 1 .
Study design and outcomes
We performed a three-part, retrospective, quasi-experimental study to assess the utility of the Verigene BC-GP assay including: (i) a 7 month baseline period prior to introduction of the Verigene BC-GP; (ii) a 7 month intervention period with Verigene BC-GP and an associated AS intervention; and (iii) a 7 month post-intervention period with Verigene BC-GP without an associated AS intervention. The primary outcome was median time to optimal therapy. Secondary outcomes included median time to effective therapy, median duration of therapy for CoNS considered to be contaminants, median length of hospital stay after blood cultures were collected, and allcause in-hospital mortality. Patients who died during the hospitalization were excluded from the length of hospital stay analysis.
Antimicrobial stewardship intervention
An AS programme (ASP), led by an infectious diseases (IDs) physician and pharmacist, had been in place at JHH since 2001. One week prior to implementation of the Verigene BC-GP, prescribers were educated about the assay via a newsletter that provided information about the test and guidelines for interpretation of results. This information was also in the JHH Antibiotic Guidelines that are available to all prescribers as a pocket guide and electronically. 16 Clinical pharmacy specialists and pharmacy residents received an additional 1 h lecture from the ASP regarding the assay. An ID pharmacist received real-time e-mail notifications regarding positive blood cultures and Verigene BC-GP results via TheraDoc V R software (Premier, Inc., Salt Lake City, UT, USA) 7 days a week (8 am-11 pm). The ID pharmacist then contacted the treating prescriber or clinical pharmacy specialist who was doing rounds with the team both to relay results and provide guidance with interpretation ( Figure S1 , available as Supplementary data at JAC Online). The on-call pharmacy resident assisted with AS interventions during the evening hours and on weekends. The differences in the AS activities during each study period are summarized in Figure 1 .
Data collection and definitions
Demographics, preexisting medical conditions, microbiology data, treatments administered and clinical outcomes were collected for all patients. Two investigators (S. E. C. and E. A.) adjudicated all cases to determine whether organisms identified from blood cultures were representative of true pathogens versus contaminants, if therapy was considered effective or optimal, and whether appropriate source control measures (e.g. drainage of infected fluid collections, removal of infected hardware) were performed. Time to optimal therapy was defined as the time from positive Gram stain to the time of initiation of the narrowest-spectrum agent that would treat the organism isolated based on national and JHH Antibiotic Guidelines (see Figure S1 for details). 16 Time to effective therapy was defined as the time from positive Gram stain to the time of initiation of the first antibiotic that was active in vitro against the organism recovered. For patients with polymicrobial bacteraemia, the clinically relevant pathogen was defined as the pathogen that was most likely to cause an infection based on source and the patient's clinical factors or pathogen that was growing in more than one blood culture (e.g. if S. aureus and coagulase-negative staphylococcus grew in blood cultures, S. aureus would be considered the pathogen).
Statistical analysis
Demographics and clinical characteristics of patients, organisms and sources of infection were compared across the three study periods. One-way analysis of variance (ANOVA) and Fisher's exact test were used for continuous and categorical variables, respectively. Outcomes were compared between both the intervention and baseline periods and the post-intervention and baseline periods using the Wilcoxon rank-sum test for continuous outcome variables and Fisher's exact test or v 2 test, as appropriate, for categorical outcomes. We further conducted multivariable regression analysis for Avdic et al.
the primary outcome, time to optimal therapy. The time to optimal therapy in the intervention and post-intervention periods was compared with the baseline period using a multivariable quantile regression model with robust variance. Variables with a P value of ,0.2 in the univariate analysis were included in the multivariable analysis. A P value of 0.05 was used to guide statistical interpretation in the overall population. All analyses were performed using Stata 13 (StataCorp, College Station, TX, USA).
Results
Patient characteristics
A total of 923 unique patients with 996 episodes of GPC bacteraemia met eligibility criteria ( Figure 2 ). Of these 996 episodes, 29% were determined to be contaminants and these were excluded from the clinical outcomes analyses; this proportion was similar across all study periods (26% baseline, 33% intervention, 28% post-intervention; P " 0.11). Clinical outcomes would not be expected to be impacted by Verigene BC-GP in 308 (31%) of episodes in which patients were already on optimal therapy at the time of positive Gram stain; these episodes were excluded from the outcome analysis. Our final analysis included 390 unique patients (125 baseline, 134 intervention, 131 post-intervention) with 400 episodes of GPC bacteraemia ( Figure 2 ). Demographic characteristics and preexisting medical conditions were generally similar between the three study periods (Table 1) . However, more patients in the post-intervention period compared with the intervention and baseline periods had Pitt bacteraemia scores 2 (72% compared with 52% and 57%, respectively; P " 0.02), were receiving immunosuppressive therapy (15% compared with 6% in each, respectively; P " 0.03), and had end-stage liver disease (15% compared with 7% and 6%, respectively; P " 0.03). Patients in the intervention period were more likely to have solid tumour with receipt of chemotherapy within 6 months compared with the baseline and post-intervention periods (11% compared with 2% and 5%, respectively, P " 0.01). Demographic characteristics and preexisting medical conditions for the entire cohort are available in the Supplementary data (Table S1 ).
Microbiology
The primary organisms causing bacteraemia were similar among the three study periods (Table 2) . Seventeen percent of bacteraemic episodes were polymicrobial. S. aureus was the most commonly isolated organism (40%, of which 38% were MRSA), followed by CoNS (19%) and all Streptococcus spp. combined (17%). E. faecalis was isolated in 14% (of which 7% were VRE) and Avdic et al.
E. faecium in 10% (of which 88% were VRE). Sources of bacteraemia were generally similar across all study periods (P " 0.31) ( Table 2 ). Of 288 bacteraemia episodes that were determined to be contaminants, CoNS was the most common contaminant (91%); other organisms judged to be contaminants were Streptococcus spp. (5%) and E. faecium (4%) ( Table S2 ).
Outcomes
A total of 400 episodes of GPC bacteraemia (127 from the baseline, 137 from the intervention and 136 from the post-intervention period) were analysed for clinical outcomes after exclusion of organisms that were determined to be contaminants (Table 3) . Based on univariate analysis, use of Verigene BC-GP did not result in significantly shorter reduced median time to optimal therapy when all organisms were combined [(26 h in the baseline versus 12 h in the intervention (P " 0.15) versus 11 h in the postintervention period (P " 0.11)]. When stratified by organism, median time to optimal therapy was shorter only for MSSA bacteraemia in both the intervention and post-intervention periods compared with the baseline period (17 versus 17 versus 50 h; P, 0.001), and for E. faecalis during the intervention period compared with the baseline period (12 versus 45 h, P " 0.02). The differences in time to optimal therapy between the intervention and post-intervention period compared with the baseline period at the 10th, 25th, 50th, 75th and 90th percentiles are shown in Table 4 . Given that the Verigene BC-GP results would be available from the microbiology laboratory starting approximately 4 h from the positive Gram stain, it would be expected that time to optimal therapy would begin to diverge in the intervention and post-intervention periods compared with baseline sometime after 4 h if clinicians are actively responding to the Verigene BC-GP results. Thus, in the 10th and 25th percentiles, encompassing patients with times to optimal therapy in the 4 h range, differences among the three periods are likely unrelated to the Verigene BC-GP results. However, in the 50th percentile, differences between the baseline and intervention period become more apparent. After adjusting for potential confounders, the time to optimal therapy was significantly shorter at the 50th, 75th and 90th percentiles in both intervention and post-intervention periods compared with the (9) 14 (10) 17 (13) Gram-negative bacilli 11 (9) 15 (11) 9 (7) Source, n (%) 0.31 bone and joint 13 (10) 13 (9) 11 (8) (3) 4 (3) 8 (6) Sustained impact of Verigene BC-GP assay on optimizing therapy JAC baseline period. In other words the time to optimal therapy was reduced significantly in patients who would otherwise achieve optimal therapy at approximately 26 h or later during the baseline period. The impact was greatest in patients with longest time to optimal therapy during the baseline period (84 h) at the 90th quantile (#24 h in the intervention period; P , 0.05 and #21 h in the post-intervention period; P , 0.01, respectively).
There were no significant differences in median time to effective therapy for all organisms, median length of stay after blood cultures were collected or in-hospital mortality among the three Excludes patients who died during the associated hospital stay. c Excludes patients who had contaminated blood cultures. (Table 3) . Median duration of therapy for CoNS that were contaminants was significantly shorter in the postintervention period compared with baseline (0 versus 19 h; P " 0.02), but not between the intervention and baseline periods (17 versus 19 h, P " 0.85) (Table S3 ).
Discussion
Our study suggests that aggressive AS interventions to facilitate clinician uptake of the use of molecular rapid diagnostic tests performed on positive blood cultures can be discontinued once clinicians become comfortable with use of the assay. Although previous studies of the Verigene BC-GP assay have demonstrated similar clinical benefits when implemented in combination with AS interventions, our study demonstrates sustainability of shorter time to optimal therapy after associated AS interventions are discontinued. [10] [11] [12] [13] [14] In the adjusted analysis, implementation of the Verigene BC-GP with AS interventions and after discontinuation of the AS interventions significantly reduced the time to optimal therapy in patients who would otherwise achieve optimal therapy at approximately 26 hours or later during the baseline period by 14-22 h. The impact was greatest in patients who had a longer delay between positive blood culture and administration of optimal therapy. For example, at the 90th percentile, time to optimal therapy was reduced by 20 h in the intervention and by 22 h in the post-intervention period for patients who would otherwise receive optimal therapy during the baseline period at approximately 84 h after positive blood culture.
When making decisions about what rapid diagnostics tests to implement, it is important to consider whether the test impacts care of patients with all organisms tested or just a subset of patients or organisms to determine whether it provides overall value. In our study, when time to optimal therapy was stratified by organism, changes to therapy among patients with MSSA was the major driver of improvements in the intervention and post-intervention periods. This reduction in time to optimal therapy is similar to other studies reporting outcomes by organism. 4, 10, [13] [14] We also observed a shorter time to optimal therapy for E. faecalis bacteraemia during the intervention period compared with baseline (12 versus 45 h; P " 0.02). It is important to note that one-third (31%) of patients in our study were already on optimal therapy at the time of positive Gram stain and results of the Verigene BC-GP assay would not be expected to impact therapy in these patients. Taken together, these findings suggest that rapid diagnostic assays may be most helpful in patients with GPC bacteraemia caused by specific organisms, particularly in cases in which where there is a clear agent of choice such as anti-staphylococcal penicillin for MSSA or ampicillin for E. faecalis. Other studies have reported significantly shorter times to appropriate therapy for patients with VRE bacteraemia, likely because standard empirical therapy does not generally cover VRE. 4, 10, 14 The value of rapid diagnostic tests may vary among institutions based on what organisms predominate in blood cultures and whether empirical therapy recommendations are optimal for these organisms.
In our study, clinicians were more likely to hold off initiating therapy for positive blood cultures that were thought to be contaminants during the post-intervention period compared with baseline (0 versus 19 h; P " 0.02), suggesting that they changed practice over time to wait for the Verigene BC-GP results before initiating therapy.
Our study did not demonstrate a decrease in the time to effective therapy. This is most likely because the majority of patients were receiving empirical antibiotics that were active against the isolated pathogens. Additionally, we found no differences in length of hospital stay after blood cultures or in in-hospital mortality, which is consistent with several other observational studies utilizing rapid molecular diagnostic assays. 13, 14 A meta-analysis of 31 studies reported decreased mortality and length of stay with use of molecular rapid diagnostic assays among studies that included Gram-negative organisms, Gram-positive organisms and multiple organisms, but not yeast. 5 In that meta-analysis, the number that had to be treated to prevent one death within 30 days was 20 patients, and AS interventions were necessary. As mortality is a relatively rare event, it may be that our study was underpowered to demonstrate any survival benefits associated with use of the Verigene BC-GP assay.
Our study has several limitations. First, it was performed at a single centre with a well-established ASP in place for over 15 years, and it is uncertain if the improved outcomes we observed in the post-intervention period are generalizable to other institutions with different patient populations, antimicrobial resistance patterns and AS practices. Second, interventions were only performed between 8 am and 11 pm, leaving a 9 h period during which realtime AS interventions did not take place. However, these would likely be the hours that such tests would not be acted upon by an AS programme in actual clinical practice. Lastly, we did not capture the impact of Verigene BC-GP and AS interventions on the deescalation of broad-spectrum antibiotics which were frequently prescribed empirically but were no longer necessary once a Grampositive organism was identified as the cause of bacteraemia.
In conclusion, real-time AS interventions during the initial months of implementation of rapid diagnostic assays coupled with clear guidance on antimicrobial selection were sufficient to lead to sustainable benefits for optimization of antimicrobial therapy in patients with GPC bacteraemia even after AS interventions were stopped. AS programmes must be judicious in determining how to parse time among multiple competing areas requiring improvement within an institution; thus, understanding what types of interventions lead prescribers to make permanent meaningful changes to how they use antibiotics is important as it allows AS programmes to move their focus to other areas. Potential reasons for the sustainability of the impact of the Verigene BC-GP assay at our institution include the presence of an established AS programme and the relative ease of interpretability of the assay itself with identification of an organism and/or a genetic element that could directly guide a change in antimicrobial therapy. Studies in other settings and with other assays are needed to further elucidate the necessity of continuous AS interventions to promote the use of rapid diagnostic tests.
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